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In this study, we investigated the hemodynamic effects and receptor- 
blocking properties of the nonselective ndothelin antagonist bosentan in 
pigs during normoxia and acute hypoxia. Hypoxic pulmonary hypertension 
was induced by decreasing the fraction of inhaled oxygen to 0.1. In a control 
group of pigs, hemodynamic parameters proved to be stable through 2 
hours of hypoxia. Infusions of endothelin-1, endothelin-3, and sarafotoxin 
6c into the pulmonary artery resulted in pulmonary and systemic vasocon- 
striction during normoxia, whereas endothelin administration during 
hypoxic pulmonary hypertension resulted in pulmonary vasodilation. After 
administration of bosentan, the vasopressor effect of endothelin-1 during 
normoxia was significantly attenuated and the pulmonary vasodilatory 
effect of endothelin-1 during hypoxia was reduced. Furthermore, the 
development of hypoxic pulmonary hypertension was significantly reduced 
by bosentan. In contrast, bosentan did not influence the pulmonary 
vasopressor esponse to the thromboxane mimic U-46619. We therefore 
conclude that vasopressor endothelin receptors seem to be activated by 
endogenous endothelin released during hypoxia, leading to an increase in 
the pulmonary vascular tone. (J Thorac Cardiovasc Surg 1996;112:890-7) 
E ndothelins (ETs) are a group of isopeptides with potent vasoactive properties, t Three isopeptides, 
ET-1, ET-2, and ET-3, have been documented; 
ET-1 is the main ET produced by the vascular 
endothelium. 2 The vascular effects of ETs are me- 
diated by at least wo endothelin receptors, ETA and 
ET B. The ET A receptor is selective for ET-1 and 
causes vasoconstriction, whereas the ETB receptor is 
nonselective and is considered to mediate ndothe- 
lium-dependent vasodilation. 3 
ET-1 elicits variable effects in different vascular 
tissues. Studies on the pulmonary circulation have 
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shown ET-1 to produce isolated vasoconstriction r 
transient vasodilation followed by vasoconstric- 
tion. <5 The effects of ET-1 on the pulmonary 
circulation vary depending on a number of factors, 
including species studied, age of studied animals, 
and vasomotor tonus of the pulmonary vascular bed; 
effects are also, at least in part, dependent on mode 
of administration) Several studies showed that low 
doses of ET-1 may produce vasodilation when the 
pulmonary vascular tone is increased by hypoxia or 
vasoconstrictive agents. 6'7 Various pathologic on- 
ditions with pulmonary hypertension have been 
found to be associated with elevated levels of ET- 
1.s, 9 In patients with congenital heart defects and 
pulmonary hypertension, elevated plasma ET-1 lev- 
els have been reported to correlate with both in- 
creased pulmonary blood flow and pulmonary vaso- 
reactivity during hypoxiaJ °' 11 In addition, these 
patients have been noted to have relatively greater 
increase in plasma levels of ET-1 during and after 
cardiopulmonary bypass, correlating with pulmo- 
nary pressure and suggesting that high endothelin 
levels may predispose patients toward pulmonary 
hypertensive crisis during the postoperative peri- 
od. 12 
We recently reported that ET infusion reduces 
pulmonary hypertension during acute hypoxia in 
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pigs. 13 To further investigate the role of ET-recep- 
tor activity in pulmonary hypoxic hypertension, in 
this study we evaluated the effects of combined 
ET A- and ETB-receptor antagonism by means of 
bosentan in pigs subjected to acute hypoxia. Bosen- 
tan, an orally active, nonselective ET antagonist, was 
developed for t4 and used in evaluation of the role of 
ETs in pathologic conditions in experimental ani- 
mals and human beings, xs First, the stability of the 
model was characterized by long-term hypoxia (2 
hours). Hemodynamic parameters during long-term 
infusion of ETs were evaluated uring normoxia nd 
hypoxia, because ET infusion has been reported to 
induce tachyphylaxisJ 6 The effects of bosentan ad- 
ministration were then evaluated uring normoxia 
and hypoxia. The ET-blocking properties were fur- 
ther studied by infusion of ET-1, ET-3, and sarafo- 
toxin 6c ($6c). $6c, a selective ETB-receptor ago- 
nist, 17 was used to evaluate the ET-receptor 
subgroups responsible for ET vasoactivity. To inves- 
tigate the selectivity of the effects observed after 
bosentan administration during hypoxia, the throm- 
boxane mimetic U-46619 was used as an alternative 
means of inducing pulmonary hypertension. 
Methods 
The ethics committee of the Karolinska Institute ap- 
proved the experiments in this study. The investigation 
conforms with the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of Labo- 
ratory Animal Resources and published by the National 
Institutes of Health (NIH publication No. 86-23, revised 
1985). 
Experimental setup. Swedish farm pigs (32 _+ 1 kg, 
approximately 4 months old) were premedicated intra- 
muscularly with 20 mg/kg ketamine. After intravenous 
anesthesia with 15 mg/kg sodium pentobarbital, the pigs 
were intubated and mechanically ventilated (Engstr6m 
respirator system 3000, Dater-Engstr6m, Bromma, Swe- 
den). A continuous infusion of fentanyl (10 
/,g. kg -~. hour-~), midazolam (100 /~g. kg -1. hour-l), 
and pancuronium bromide (150/,g. kg -~- hour -~) main- 
tained anesthesia and provided skeletal muscle relaxation. 
Inspired ventilatory volumes were adjusted to maintain a
carbon dioxide tension of 4.0 to 5.0 kPa. During normoxia, 
the pigs were ventilated with room air; hypoxia was 
created by switching to a gas mixture of 10% oxygen in 
90% nitrogen to increase pulmonary vascular tone. The 
fraction of inhaled oxygen was monitored (Serve gas 
monitor; Siemens AG-Bereiche Medizinische Technik, 
Erlangen, Germany) throughout he experiments. Ac- 
etated Ringer's olution (100 to 150 ml/hour) was admin- 
istered intravenously, and body temperature was kept at 
37 ° C with a heating pad. Mean systemic artery pressure 
(MAP) was measured through a catheter in the left 
femoral artery. A Swan-Ganz catheter (Baxter Healthcare 
Corp., Edwards Div., Irvine, Calif.) was introduced 
through the right jugular vein for measurement of mean 
pulmonary artery pressure (MPAP), pulmonary capillary 
wedge pressure (PCWP), and central venous pressure 
(CVP). Hemodynamic measurements were monitored 
and recorded continuously (pressure transducer, Peter 
von Berg Medizintechnik, GmbH, Eglharting, Germany; 
pressure monitor, Hewlett-Packard 78342 A; Hewlett- 
Packard GmbH (Peter von Berg Medizintechnik GmbH); 
pressure recorder, Gould ES 1000, Gould Electronique, 
Longjuneau, France). Cardiac output (CO) was measured 
in duplicate by thermodilution by means of a cardiac 
output computer (COM-2; Baxter). Pulmonary vascular 
resistance (PVR) was calculated as (MPAP - PCWP)/ 
CO; systemic vascular resistance (SVR) was calculated as 
(MAP - CVP)/CO. Arterial and mixed venous blood 
samples were obtained simultaneously for measurements 
of blood gas tension and pH. ET-1, ET-3, $6c (Peninsula 
Laboratories, Inc., Belmont, Calif.), dissolved in sterile 
water, and the thromboxane mimic U-46619 (Sigma 
Chemical Company, St. Louis, Mo.) were infused through 
the Swan-Ganz catheter into the right ventricle. Bosentan 
(Hoffmann-La Roche & Co. AG, Basel, Switzerland) 
dissolved in 2 ml dimethylsulfoxide and diluted with 48 ml 
sterile water was infused through the left femoral vein. 
Blood samples for measurement of circulating ET were 
obtained simultaneously from the pulmonary artery and 
descending aorta for determination of plasma concentra- 
tion of ET-1 by radioimmunoassay; details and character- 
ization of this assay are punished elsewhere. 18
Study protocol 
Hemodynamic effects of 2 hours of hypoxia. A control 
group of six pigs was subjected to hypoxia only for 2 hours. 
Effects" of 2-hour infusion of ET-1 and ET-3 during 
normoxia and hypoxia. The effects of 2-hour infusion of 
ETq and ET-3 (25 ng. kg ~ • min -1) were studied in two 
separate groups of pigs (n = 4 in each group) during 
normoxia. After cessation of the infusion, the pigs were 
left to restfor 2 hours and thereafter subjected to hypoxia, 
during which ET-1 or ET-3 was again infused for 2 hours 
at 25 ng. kg -1. min -1. The dose of ET-1 was chosen on 
the basis of our previous tudy, in which low-dose infusion 
was found to decrease MPAP and PVR. 13 
Effects of $6c infusion during normoxia nd hypoxia. To 
further evaluate the involvement of the ETB receptor in 
the vasodilator response to ET-1 infusion during hypoxia, 
$6c was infused at increasing doses (10, 25, 50, and 100 
ng. kg -1. rain -~, 10 minutes each dose, n = 6) during 
normoxia nd (after a resting period of 2 hours) during 
hypoxia. 
Effects of ET infusion after bosentan administration 
during norrnoxia. The dose-response r lationship of in- 
fused ET-1 (10, 25, 50, and 100 ng-kg -1.min -1, 10 
minutes each dose) was established, uring normoxia in 
control animals (n = 8) and after intravenous bolus 
injection of bosentan at 3 mg/kg (n = 4) or 10 (n = 4) 
mg/kg, administered 30 minutes before ET infusion. 
Effects of bosentan on pulmonaly hypertension i duced by 
hypoxia or U-46619. In addition, the response to 15 min- 
utes of hypoxia was evaluated before and 30 minutes after 
bosentan administration i separate groups of experi- 
ments (n = 4 for 3 mg/kg intravenous bosentan and n = 8 
for 10 mg/kg intravenous bosentan). The effects of 
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Table i, Effects of continuous infusions of ET-1 (25 rig" kg -1 • rain z) or ET-3 (25 ng. kg -1 • rain -1) in the 
pulmonary artery on hemodynamic parameters during hypoxia 
ET-1 ET-3 
Hypoxia 30 rain 60 rain 90 rain 120 rain Hypoxia 30 rain 60 rain 90 rain 120 rain 
MAP(mmHg)  129+8 141+6 148+_4 146-+8 137 +15 115+_10 128_+3 121_+13 124,+15 114--1 
MPAP (ram Hg) 52 _+ 5 38 -+ 3* 39 ± 4 40 .+ 3 39 ± 3 46 -+ 2 35 .+ 2* 35 _+ 1" 38 +_ 3 39 + 4 
PCWP (ram Hg) 18 _+ 4 11 -2-_ 1 11 .+ 1 10 .+ 1 10 + I 15 +_ 3 14 -+ 3 12 -+ 2 12 + 1 13 _+ 1 
CVP (mmHg) 12.+ 1 10,+ 1 9 .+ 1 9 ± 1 7,+ 1" 12 +_ 1 12_+ 3 10 + 2 11 ± 2 12 +_ 1 
CO(L/rain) 4.2+0.2 4.5.+0.2 3.8_+0.3 3.8_+0.5 3.0,+0.5 4.2_+0.2 5.0,+0.8 4.1,+0.2 4.1_+0.6 4.2+0. 
SVR (ram Hg • rain • L -1) 29 ± 3 29 +_ 2 37 _+ 2 38 + 4 46 + 8* 21 + 3 24 _+ 2 24 ,+ 3 25 + 2 22 .+ 3 
PVR(mmHg.min .L  -t)  8.4±0.8 5.7,+0.4" 7.7+_0.9 8.2+_1.0 10±1.3 8.2-+0.6 4.9+_0.4' 5.3+0.4 5.7.+0.5 5.7_+0. 
HR(beats/min) 135 +26 126+_14 125_+18 135_+26 130.+28 130 +7 124+21 119 +14 130+_21 120+2 
Hemodynamic parameters were measured before infusion (control) and after 30, 60, 90, and 120 minutes of infusion. Data presented as mean --_ standard 
error of the mean. HR, Heart rate. 
*p < 0.05, Friedman test for several related samples, versus values before infusion, 
U-46619 (250 ng.kg -~. rain -~) infused for 15 minutes 
were evaluated in control pigs (n = 5) and in animals 
receiving 10 mg/kg bosentan (n = 4). The dose of U-46619 
was chosen on the basis of preliminary experiments (n = 
2, not shown) in which U-46619 was found to yield an 
increase in PVR in the range of that of hypoxia. 15 
ET infusion during hypoxia fter bosentan administration. 
The effects of ET-1 infusion (25 and 100 
rig" kg -~" min -J) during hypoxia were studied in a con- 
trol group (n = 4) and a group of pigs receiving 10 mg/kg 
bosentan intravenously (n = 4). After 5 minutes of 
hypoxia, the hemodynamic parameters were stable and 
baseline values during hypoxia were obtained. After 10 
minutes of ET-1 infusion (25 ng. kg -~. min-1), hemody- 
namic measurements were repeated. The ET-1 dose was 
then increased (100 ng. kg -a • rain-l), and an additional 
hemodynamic recording was made after 10 minutes. 
The time intervals and doses of ET-1 infusions were 
based on results of the 2-hour infusions and of previous 
work. ~3 
Statistical analysis, Results are presented as mean (_+ 
standard error of the mean), The Friedman test for 
several related samples or the Mann Whitney U test was 
used for statistical evaluation. A p value lower than 0.05 
was considered significant. 
Results 
Hemodynamic effects of 2 hours of hypoxia. In- 
duction of hypoxia resulted in prompt increases in 
MPAP (from 25 + 2 to 35 + 1 mm Hg) and PVR 
(from 3.0 + 0.1 to 5.4 _+ 0.3 mm Hg" rain -1-  L-~; 
p < 0.01), a decrease in SVR, and an increase in 
heart rate. No clear-cut effects on PCWP (i2 +_ 1 to 
13 _+ 1 mm Hg), CO (4.2 + 0.3 to 5.0 _+ 0.3 L/rain), 
and CVP (10 +_ 1 to 11 +_ i mm Hg) were observed. 
The increases in MPAP and PVR remained un- 
changed during prolonged hypoxia (after 2 hours, 
MPAP 42 + 3 mm Hg, PVR 5.5 _+ 0.6 mm 
Hg- ra in  -1 .  L - t ) .  Hypoxia decreased the arterial 
oxygen tension to 3.4 + 0.3 kPa. 
Effects of 2 hours of infusion of ET-1 and ET-3 
during normoxia and hypoxia. Infusion of ET-1 (25 
ng .kg  -~.min  - j )  for 2 hours during normoxia 
evoked a gradual increase in PVR and SVR, 
whereas CO decreased (MPAP 25 + 1 to 29 _+ 3 mm 
Hg after 2 hours infusion and PCWP 12 _+ 1 to 11 + 
1 mm Hg; Fig. 1). ET-3 (25 ng-kg- l -min  -1) 
evoked principally similar effects on SVR and CO, 
whereas no increase in PVR was observed (MPAP 
26 + 1 to 27 + 3 mm Hg after 2 hours infusion and 
PCWP 11 _+ 1 to 13 _+ 1 mm Hg; Fig. i). During 
hypoxia, infusion of either ET-1 or ET-3 decreased 
PVR (Table I). This response diminished after 
prolonged infusion. No major effects on CO were 
observed after 2 hours of infusion of ET-1 or ET-3 
in the hypoxic pigs, whereas SVR increased after 
120 minutes of ET-1 infusion (Table I). Infusion of 
vehicle had no hemodynamic effects. ~3 
Effects of $6c infusion during uormoxia and 
hypoxia. $6c infusion (10, 25, 50, and 100 
ng" kg -1 • rain -1) during normoxia evoked a dose- 
dependent increase in PVR and SVR, whereas 
CO decreased (MPAP 26 +_ 1 to 27 + i mm Hg 
after 100 ng.  kg - I  • rain -1 infusion and PCWP 12 
_+ 1 to 16 +_ 1 mm Hg; Fig. 2). When PVR was 
increased by hypoxia, $6c infusion at the lower 
doses (10 to 50 ng.  kg -1 • rain -1) caused an atten- 
uation of this PVR increase (MPAP 41 _+ 2 before 
infusion to 32 +_ 1 mm Hg after 50 
ng- kg -1 • rain - I  infusion and PCWP 13 + I to 15 
+_ 1 mm Hg), whereas effects on SVR and CO 
remained unchanged. 
Effects of ET infusion after bosentan administra- 
tion during normoxia. Intravenous administration 
of bosentan (3 or 10 mg/kg) caused a decrease in 
MAP and SVR but did not influence MPAP, PVR, 
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CO, or heart rate (Table II). Bosentan inhibited the 
increases in PVR and SVR evoked by ET-1 during 
normoxia (Fig. 3). The vehicle for bosentan, tested 
during normoxia nd hypoxia (n = 2), was found to 
have no hemodynamic effects. 
Effects of bosentan on puhnonary hypertension 
induced by hypoxia or U-46619. When hypoxia was 
established after bosentan administration, there was 
a reduction of the vasopressor response in the 
pulmonary circulation. At the higher dosage of 
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Table II. Influence of intravenous bosentan administration at 3 and 10 mg/kg on hemodynamic parameters 
during normoxia nd hypoxia 
Normoxia Hypoxia 
Bosentan Bosentan 
Control 3 mg/kg 10 mg/kg Control 3 mg/kg 10 mg/kg 
MAP (mm Hg) 128 _+ 5 98 _+ 7* 95 +_ 6* 118 ± 5 88 _+ 4t 94 ± 5t 
MPAP (ram Hg) 20 _+ 2 22 + 1 17 + 1 43 _+ 2 42 -+ 2 26 -+ 25 
PCWP(mmHg)  12_+2 11_+1 9+_1 13_+1 12+_1 9-+1 
CVP (mmHg) 8 + 1 7 ± 2 6 ± 1 10 ± 1 10 ± I 8 + 1 
CO (L/rain) 3.6 + 0.3 3.5 ± 0.4 3.6 _+ 0.4 4.2 +_ 0.2 4.9 _+ 0.7 4.4 -- 0.5 
SVR (mm Hg- min" L -1) 35 ± 2 27 -- 4 27 ± 37 25 + 2 17 ± 27 21 ± 2? 
PVR (mm Hg" min" L 1) 2.4 ± 0.3 3.1 _+ 0.1 2.2 _+ 0,3 7.6 ± 0.5 6.4 _+ 0.6 4.3 ± 0.7t 
HR (beats/min) 91 + 4 82 ± 3 87 ± 9 123 _+ 8 120 _+ 12 108 _+ 12 
Data presented as mean +- standard error of the mean. HR, Heart rate. 
*p < 0.01, Friedman test for several related samples, versus values before infusion. 
?p < 0.05, Friedman test for several related samples, versus values before infusion. 
-~p < 0.001, Friedman test for several related samples, versus values before infusion. 
bosentan (10 mg/kg), MPAP and PVR during hy- 
poxia were significantly lower than in control ani- 
mals (Table II). U-46619 caused a rapid increase in 
MPAP (26 ± 1 to 54 ± 8 mm Hg) and PVR (3.9 + 
0.4 to 12.2 ± 2.8 mm Hg. min- L-l). Bosentan (10 
mg/kg) did not influence the response to U-46619 
(MPAP 52 + 2 mm Hg and PVR 9.5 + 1.2 mm 
Hg- min" L-l). 
ET infusion during hypoxia after bosentan admin- 
istration. ET-1 infusion (25 or l00 ng. kg -1" rain -1 
for 10 minutes) caused a reduction of PVR during 
hypoxia (Fig. 4). The increase in PVR during hy- 
poxia was reduced after bosentan administration, 
and subsequent infusion of ET-1 did not evoke any 
further reduction of the PVR. 
Plasma ET-1 levels and blood gas values. Neither 
ET nor bosentan influenced arterial or venous blood 
gas values (pH, oxygen tension, and carbon dioxide 
tension) during normoxia or hypoxia (not shown). 
Bosentan administration i creased both the arterial 
and venous circulating ET-1 levels (8.4 ± 1.2 to 
24.1 _+ 4.6 fmol/ml in the aorta and 8.1 ± 1.8 to 21.1 
± 2.5 fmol/ml in the pulmonary artery). The levels 
of circulating ET-1 did not change significantly 
during hypoxia (as long as 2 hours, not shown). 
Discussion 
In this study, we evaluated the involvement of ET 
in hypoxic pulmonary hypertension by means of a 
large-animal in vivo model. Previous work has 
shown that repeated 15-minute periods of hypoxia 
in pigs produce stable, reproducible hemodynamic 
changes; namely, consistent increases in MPAP and 
PVR. 13 The main effect of ET-1, ET-3, and $6c Oil 
the pulmonary and systemic vascular beds is vaso- 
constriction during normoxic conditions. The con- 
comitant decrease in CO could be related to the 
increase in SVR, although coronary vasoconstric- 
tion 19 or a direct negative inotropic effect 2° cannot 
be excluded. In contrast, when the PVR was in- 
creased uring hypoxia, exogenous ET-1, ET-3, and 
$6c all reduced PVR. This effect (in the case of ET-1 
and ET-3) lasted at least 30 minutes, suggesting that 
tachyphylaxis does not occur during this time. 13 The 
observation that changes in PVR in all major as- 
pects were accompanied by changes in MPAP sup- 
ports the contention that this reflects active alter- 
ations in the vasomotor tone of the pulmonary 
vascular bed. In accord, a previous study demon- 
strated pulmonary vasodilation without any evi- 
dence of short-term tolerance during ET-1 admin- 
istration after hypoxic pulmonary hypertension 
when CO was kept constant. 21 
This study demonstrated that ET antagonism with 
bosentan reduces both the dose-dependent pressor 
response to ET-l-infusion in the pulmonary and 
systemic irculation during normoxia nd the devel- 
opment of pulmonary hypertension during hypoxia. 
In addition, the vasodilator capacity of ET during 
hypoxia-evoked increases in PVR is attenuated by 
bosentan. The selectivity of bosentan for ET recep- 
tors was supported by the finding that the pulmo- 
nary vasopressor response to U-46619 remained 
unchanged after bosentan administration. 
Previous studies of the hemodynamic effects of 
ET-1 on the pulmonary circulation demonstrated 
inconsistent and partially conflicting results. Low 
doses of ET-1 produced pulmonary vasodilation in 
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animals (E) and after intravenous administration of 3 
mg/kg ((D) or 10 mg/kg (A) bosentan. Error bars represent 
standard error of the mean. Asterisk indicates p < 0.05, 
Mann-Whitney U test. 
the newborn piglet, whereas higher doses elicited 
vasoconstriction, s In intact newborn lambs, ET-1 
produced pulmonary vasodilation during hypoxic 
pulmonary hypertension, 22 whereas in fetal sheep 
ET-1 decreased the pulmonary vascular resistance 
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absence (B) or presence (A) of bosentan (10 mg/kg). Error 
bars represent standard error of the mean. Asterisk indi- 
cates p < 0.05 versus hypoxia, Friedman test for several 
related samples. 
when infused into the pulmonary artery but pro- 
duced vasoconstriction when infused into the supe- 
rior vena cava. 23 Furthermore, in older animals 
(calves and adult pigs), ET-1 dilated the pulmonary 
circulation during hypoxic pulmonary vasoconstric- 
tion.21, x3 The heterogeneity of the ET-receptor 
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population could explain some of the differences in 
effects of ET-1 observed in the pulmonary circula- 
tion. It has therefore been suggested that the pul- 
monary vasodilator effect of ET-1 in low doses 
during acute hypoxia is mediated by ETB receptors 
located on the endothelium. 3' 13 Activation of ET 
receptors could subsequently produce vasoconstric- 
tion or vasodilation, depending on dose of ET 
administered, mode of administration, species tud- 
ied, and vascular bed studied. This study demon- 
strates that the predominant response to activation 
of ET receptors in the pulmonary circulation in pigs 
during acute hypoxia is vasoconstriction, because 
bosentan resulted in a reduction of the vasoconstric- 
tor response. This suggests that vasocontractile ET 
receptors on vascular smooth muscle are activated 
by ET released during acute hypoxia, which is in 
accord with the primarily abluminal release of en- 
dogenous ET. 24 Conversely, the vasodilator re- 
sponse to ET-1 administered in low doses during 
acute hypoxia could be attributed to activation of 
ET B receptors on the vascular endothelium. 13Our 
results with $6c also imply that the vasodilator effect 
during hypoxia is indeed mediated by ETB-receptor 
activation, although $6c has also been shown to 
cause vasoconstriction of isolated blood vesselsY 
Autoradiographic studies, however, have shown a 
predominance of ET A receptors and a lack of ET B- 
mediated vasoconstriction in human pulmonary arter- 
ies. The attenuation of SVR during normoxia by 
bosentan, independent of other influences, suggests 
the existence of an endogenous vasocontractile " ndo- 
thelin tone" in the systemic irculation. It is generally 
considered that the pulmonary circulation is dilated 
during normoxia, a contention supported in this study 
by the observation that PVR at normoxia remained 
unchanged after bosentan administration. 
ET antagonism with bosentan results in a clear- 
cut increase in the levels of circulating ET-1, which 
is in accord with previous findings. 26 The absence of 
increases in the levels of circulating ET during 
hypoxia may be explained by abluminal release of 
ET to the vascular smooth muscle cells, 24 although 
peripheral plasma concentration may not accurately 
reflect the concentration of ET at local release sites. 
Furthermore, prolonged hypoxia may be needed to 
increase circulating levels of ET. 27'28 In human 
beings, the circulating plasma levels of ET-1 are low 
under normal conditions but elevated in a variety of 
pathologic onditions, including pulmonary hyper- 
tension. 29'3° The beneficial effects of combined 
ET A- and ETB-receptor antagonism in clinical con- 
ditions associated with pulmonary hypertension 
therefore remain to be established. Bosentan has 
interesting properties in this context; bosentan is the 
first orally active, nonselective, nonpeptide ET-re- 
ceptor antagonist. 
REFERENCES 
1. Yanagisawa M, Kiruhara H, Kimura S, Tomobe Y, Koba- 
yashi M, Mitsui Y, et al. A novel potent vasoconstrictor 
peptide produced by vascular endothelial cells. Nature 1988; 
332:411-5. 
2. Inoue A, Yanagisawa M, Kimura S, Katsuya Y, Miyauchi T, 
Goto K, et al. The human endothelin family: three structurally 
and pharmacologically distinct isopeptides predicted by three 
separate genes. Proc Natl Acad Sci U S A 1989;86:2863-7. 
3. Stewart DJ, Langleben D. Endothelin and pulmonary hyper- 
tension. In: Lfischer TF ed. The endothelium in cardiovas- 
cular disease. New York: Springer-Verlag 1995:184-95. 
4. Horgan M J, Pinheiro JM, Malik AB. Mechanism of endo- 
thelin-1 induced pulmonary vasoconstriction. Circ Res 1991; 
69:157-64. 
5. Bradley LM, Czaja JM, Goldstein RE. Circulatory effects of 
endothelin i  newborn piglets. Am J Physiol 1990;259(5 Pt
2):H1613-7. 
6. Lippton HL, Gordon CA, McMurtry IF, Hyman AL. 
Pulmonary vasodilation to endothelin isopeptides i medi- 
ated by potassium channel activation. J Appl Physiol 
1991;70:947-52. 
7. Hasunuma K, Rodman DM, O'Brien RF, McMurtry IF. 
Endothelin 1causes pulmonary vasodilatation in rats. Am J 
Physiol 1990;259(1 Pt 2):H48-54. 
8. Cernacec P, Stewart DJ. Immunoreactive endothelin hu- 
man plasma: marked elevation i  patients with cardiogenic 
shock. Biochem Biophys Res Commun 1989;161:562-7. 
9. Yoshibayashi M,Nishioka K, Nakao K, Saito Y, Matsumura M,
Ueda T, et al. Plasma endothelin concentrations i  patients with 
pulmonary hypertension associated with congenital heart de- 
fects: evidence for increased production ofendothelin pul- 
monary circulation. Circulation 1991;84:2280-5. 
10. Vincent JA, Ross RD, Kassab J, Hsu JM, Pinsky WW. 
Relation of elevated plasma endothelin i  congenital heart 
disease to increased pulmonary blood flow. Am J Cardiol 
1993;71:204-7. 
11. Allen SW, Chatfield BA, Koppenhafer SA, Schaffer MS, 
Wolfe RR, Abman SH. Circulating immunoreactive endothe- 
lin-1 in children with pulmonary hypertension. Am Rev 
Respir Dis 1993;148:519-22. 
12. Komai H, Adiata IT, Elliott MJ, de Leval MR, Haworth SG. 
Increased plasma endothelin-1 after cardiopulmonary bypass 
in patients with pulmonary hypertension a d congenital heart 
disease. J Thorac Cardiovasc Surg 1993;106:473-8. 
13. Liska J, Holm P, ()wall A, Franco-Cereceda A. Endothelin 
reduces hypoxic pulmonary hypertension in pigs in vivo. Acta 
Physiol Scand 1995;154:489-98. 
14. Clozel M, Breu V, Gray GA, Kalina B, L6ttter BM, Burri K, 
et al. Pharmacological haracterization f bosentan, a new 
potent orally active nonpeptide endothelin receptor antago- 
nist. J Pharmacol Exp Ther 1994;270:228-35. 
15. Kiowski W, Sfitsch G, Hunziker P, Mfiller P, Kim J, Oechslin 
E, et al. Evidence for endothelin-l-mediated vasoconstric- 
tion in severe chronic heart failure. Lancet 1995;345:732-6. 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 112, Number 4 
Holm et al. 897  
16. Lippton HL, Hauth TA, Cohen GA, Hymn AlL. Functional 
evidence for different endothelin receptors in the lung. 
J Appl Physiol 1993;75:38-48. 
17. Williams DL, Jones KL, Pettibone DJ, Lis EV, Clineschmidt 
BV. Sarafotoxin 6c: an agonist which distinguishes between 
endothelin receptor subtypes. Biochem Biophys Res Com- 
mun 1991;175:556-61. 
18. Franco-Cereceda A, Rydh M, Lou Y, Dalsg~rd CJ, Lundberg 
JM. Endothelin as putative sensory neuropeptide in the 
guinea-pig: different properties in comparison with calcitonin 
gene-related peptide. Reg Pept 1991;32:253-65. 
19. Franco-Cereceda A. ET- and NPY-induced vasoconstriction 
of human coronary arteries in vitro. Br J Pharmacol 1989;97: 
968-72. 
20. Franco-Cereceda A, Matran R, Lou Y-P, Lundberg J. Oc- 
currence and effects of endothelin in the guinea pig cardio- 
pulmonary tissue. Acta Physiol Scand 1990;137:539-47. 
21. Deleuze PH, Adnot S, Shiiya N, Roudot Thoravel F, Edda- 
hibi S, Braquet P, et al. Endothelin dilates bovine pulmonary 
circulation and reverses hypoxic pulmonary vasoconstriction. 
J Cardiovasc Pharmacol 1992;19:354-60. 
22. Wong J, Vanderford PA, Fineman JR, Chang R, Soifer SJ. 
Endothelin-1 produces pulmonary vasoditation in the in- 
tact newborn lamb. Am J Physiol 1993;265(4 Pt 2):H1318- 
24. 
23. Chateld BA, McMurtry IF, Hall SL, Abman S. Hemody- 
namic effects of endothelin-1 on ovine fetal pulmonary 
circulation. Am J Physiol 1991;261 (Regulatory Integrative 
Comp Physiol 30):R182-7. 
24. Seo B, Oemar BS, Siebenmann R, yon Segesser L, Ltischer 
TF. Both ET A and ET B receptors mediate contraction to 
endothelin-1 in human blood vessels. Circulation 1994;89: 
1203-8. 
25. Fukuroda T, Kobayashi M, Ozaki S, et al. Endothelin recep- 
tor subtypes in human versus rabbit pulmonary arteries. 
J Appl Physiol 1994;76:1976-82. 
26. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, 
Nowotny PJ, et al. Polar secretion of endothelin-1 by cultured 
endothelial cells. J Biol Chem i992;267:16066-8. 
27. Goerre S, Wenk M, B~irtsch P, Lfischer TF, Niroomand F, 
Hohenhaus E, et al. Endothelin-1 in pulmonary hypertension 
associated with high-altitude xposure. Circulation 1995;90: 
359-64. 
28. Kourembanas S, Marsden PA, McQuillan LP, Faller DV. 
Hypoxia induces endothelin gene expression and secretion 
in cultured human endothelium. J Clin Invest 1991;88: 
1054-7. 
29. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased 
plasma levels of endothelin-1 in pulmonary hypertension: 
marker or mediator of disease? Ann Intern Med 1991;!141: 
464-9. 
30. Chang H, Wu GJ, Wang SM, Hung CR. Plasma endothelin 
levels and surgically correctable pulmonary hypertension. 
Ann Thorac Surg 1993;55:450-8. 
